Hemophilia Market Snapshot: Long-Acting Products Poised To Transform Market
Executive Summary
The staid hemophilia market may soon see the introduction of long-acting factor products, reshuffling segment shares, moving patients to prophylactic use, and expanding an already substantial global market. Biogen will be first to market, followed by established players. But will the improvements be enough to sway providers and payers?